– Exacis uses proprietary mRNA-based cell engineering to develop off-the-shelf immune cell therapies for cancer treatment from induced pluripotent stem cells (iPSCs)

CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ — Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis’ innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer. The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.